{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "MOH",
  "name": "Molina Healthcare, Inc.",
  "url": "https://frontierpicks.com/dossiers/MOH/",
  "json_url": "https://frontierpicks.com/dossiers/MOH.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a4",
    "n": 4
  },
  "current_thesis": "Medicaid-trough thesis passed its 2026-07-22 test (FY26 adjusted EPS guided to ≥$5.25), but the price leg expressing it broke: the week ending 2026-08-21 closed $200.29, under the $205 floor of the late-June breakout gap. What is left is management's >$10 2027 earnings-power framing against a Hold-heavy sell-side whose mean target ($202.44, 2026-08-18) sits at the market, with no dated company event until the ~2026-10-22 Q3 print.",
  "invalidation_trigger": "A weekly close below $188 takes out the pre-breakout $188–192 shelf and ends the trough-recovery leg. Secondary: a Q3 print (~2026-10-22 est.) guiding FY26 adjusted EPS back under $5.25 or lifting the 92.6% consolidated MCR guide.",
  "catalyst_date": null,
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "managed-care-health-services"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Results are released after the close with the call the following morning (Q2: 2026-07-22 release, 2026-07-23 8:00 ET call) — the move prices overnight.",
    "GAAP and adjusted EPS diverge materially (Q2 2026: $1.19 vs $1.51); the trough-year framework is stated on adjusted EPS.",
    "Moved into the S&P MidCap 400 at the 2026-07-16 reconstitution; passive sponsorship runs through mid-cap vehicles.",
    "ACA enhanced premium tax credits expired 2025-12-31; a House-passed three-year extension (2026-01-08) is still awaiting Senate action.",
    "Twice-a-year Medicaid eligibility redeterminations begin December 2026 — a standing membership-attrition mechanism into 2027."
  ],
  "body_markdown": "## Current Thesis\nThe fundamental leg passed its test; the price leg that expressed it did not hold. Q2 2026 (released after the close on 2026-07-22, call 2026-07-23) delivered adjusted EPS of $1.51 against GAAP $1.19 on $10.2B of premium revenue, and full-year adjusted EPS guidance went up $0.25 to at least $5.25 — the first raise of this cycle against the ≥$5.00 floor set in the Q4 2025 guide-slash. Since then the tape has gone the other way. Shares fell 4.4% on 2026-08-17 to $203.06 with no company announcement or filing in that window, and the week ending 2026-08-21 closed at $200.29 — below the $205 shelf left by the late-June breakout gap, which is the level the prior frame identified as the structural break. RSI(14) is 54.6 versus 63.3 measured to 2026-08-14; the three-month price change has compressed to +8.8% from +14.8% over the same span a week earlier. Price sits 17.5% under the $242.88 52-week high. What an investor is buying from here is management's 2027 earnings-power framing above $10 per share (stated on the 2026-07-23 call, not a formal guide) against a Hold-dominant sell-side whose aggregated target sits at the market, with the next dated company event roughly nine weeks out.\n\n## Bull Case\n- **The trough number moved up (2026-07-22):** FY26 adjusted EPS guided to ≥$5.25 from ≥$5.00, with GAAP guidance also raised. Guidance rose into the print investors feared.\n- **Medicare duals inflected (call, 2026-07-23):** FY Medicare MCR guidance cut to 92.2% from 94.0%, lifting segment EPS contribution by $1.50 to $0.25 — the largest single swing inside the raise.\n- **Medicaid cost trend held (Q2, 2026-07-22):** Medicaid MCR 92.7% against an FY guide of 92.9%; consolidated FY MCR guide untouched at 92.6% even as Q2 consolidated MCR ran 92.2% versus 90.4% a year earlier.\n- **A stated 2027 number (call, 2026-07-23):** earnings power above $10 per share, built from roughly $4.50 embedded in the Florida contract and the MA-PD reversal plus about $0.75 from Marketplace returning to break-even. This is the forward leg; it is management framing and carries no guidance status.\n- **Unpriced policy optionality:** the House passed a three-year extension of the enhanced ACA premium tax credits 230–196 on 2026-01-08 (AHA, Ballotpedia coverage); the Senate has not acted. Marketplace is currently carried at a −$0.75 FY EPS contribution, so a Senate move re-prices the segment most damaged in the Q2 reset.\n- **July fair-value marks sit above spot:** RBC $248 (2026-07-09), Truist $250 (2026-07-14), Wells Fargo $235 (2026-07-13), TD Cowen $230 (2026-07-14), BofA $250 on the 2026-06-24 Underperform→Buy double upgrade. Caveat below: those marks do not reconcile with the mid-August aggregations.\n\n## Bear Case\n- **Marketplace deteriorated faster than the repricing fixed it.** FY Marketplace MCR guidance was raised to 90.0% from 85.5% on 2026-07-23, and CEO Joseph Zubretsky told the call, \"We underestimated the stickiness of high-cost members,\" despite rate increases of 15%–45%. The segment swung from a projected +$0.75 contribution to −$0.75.\n- **The ACA book is shrinking to a stub.** Molina expects roughly 250,000 ACA enrollees at year-end 2026, with further market exits planned for 2027 (Healthcare Dive, 2026-07-23). Enhanced premium tax credits expired 2025-12-31 and roughly 3 million people have left the exchanges since.\n- **The sell-side mean has drifted to the price.** An aggregation summarized on 2026-08-18 showed a consensus Hold with a mean target of $202.44 and a $129–$220 range; a different aggregation accessed 2026-08-15 showed a mean near $209 with a $147–$266 range and a 15 hold / 3 buy / 1 sell mix. The two are not reconcilable with the named July targets — $250 exceeds the top of the 2026-08-18 range — so at least one constituent set is stale or partial. Both means bracket rather than clear the 2026-08-21 close of $200.29.\n- **Ratings never followed the targets.** July's raises to $230–250 kept Hold/Equal-Weight/Sector-Perform labels, and Barclays cut to $184/Underweight on 2026-07-09.\n- **Sector cost trend prices MOH first.** On Elevance's mid-July Q2 report, Health Benefits adjusted operating margin fell to 3.6% from 5.0% and segment operating profit dropped by nearly half; MOH traded down as much as 9% premarket that morning, the steepest move among major peers.\n- **Membership is contracting.** Q2 total membership declined year over year even as EPS beat and guidance rose, against a base of roughly 4.9 million members.\n\n## Setup & Price Structure\n- Reference close 2026-08-21: $200.29, 17.5% below the $242.88 52-week high, RSI(14) 54.6, three-month price change +8.8%.\n- Sequence into the break: $212.43 on 2026-08-14 → a 4.4% decline on 2026-08-17 to $203.06 (per the GuruFocus summary carried 2026-08-18) → $200.29 on 2026-08-21. No Form 4 or other filing appears in the recent window, and no company release explains the 08-17 move; the available coverage names none.\n- The $205 area marked the floor of the late-June breakout gap. With that gone on a weekly close, the next observable structure below is the $188–192 shelf that contained the name before the June move.\n- **The narrative is maturing.** Dating it: the last company-generated headline is the 2026-07-23 call; intervening coverage is a 15-year backward-looking-return piece (2026-08-13) and a whale-activity options-flow item (2026-08-18); aggregated targets sat at the price on 2026-08-18; nothing dated moves the number until roughly 2026-10-22. The narrative is well known and still supported by the Q2 numbers, while the flow that carried June–July has stopped paying.\n- **Crowding and positioning observables:** mean target $202.44 versus a $200.29 close (2026-08-18 / 2026-08-21); ratings mix dominated by Hold; approximately 98.5% of float held by institutions (GuruFocus, 2026-08-18) on a market capitalization near $10.7B; S&P MidCap 400 membership since the 2026-07-16 reconstitution, so passive sponsorship runs through mid-cap vehicles; no earnings date inside the next 30 days; no insider transactions or equity issuance visible in the recent filing feed.\n\n## Catalyst Calendar (next 30 days)\n\n- **2026-08-23 → 2026-09-22: no confirmed company-scheduled event.** Nothing dated is on the calendar in this window; the datapoints that arrive are peer guidance updates and state Medicaid rate actions, which have no schedule.\n- **~2026-10-22 (est.):** Q3 2026 results, released after the close with the call the following morning. First test of the ≥$5.25 FY26 adjusted EPS guide, the 92.6% consolidated MCR guide, and whether the Marketplace loss stops at −$0.75.\n- **2026-11-01:** ACA open enrollment opens for the 2027 plan year — sizes the Marketplace book against the ~250,000 year-end 2026 enrollee expectation and the planned 2027 exits.\n- **~2026-12-01 (est.):** twice-a-year Medicaid eligibility redeterminations begin, a recurring attrition mechanism on the base carrying the $5.75 Medicaid segment EPS contribution.\n\n## Elapsed catalysts\n\n- **Undated, live:** Senate action on the enhanced-premium-tax-credit extension the House passed 230–196 on 2026-01-08. No vote is scheduled; it is optionality, not a date. *(passed 230d ago)*\n\n## What Would Change Our Mind\nThe structure that carried the June–July leg is already gone: the week ending 2026-08-21 closed at $200.29, under the $205 gap floor, which resolved the prior frame's break condition on the downside. The question now is whether the $188–192 pre-breakout shelf holds. A weekly close below $188 would take out that shelf and end the trough-recovery leg outright, at which point the label moves from maturing toward failed. On the other side, a weekly close back above $213 would reclaim the broken gap and put the June structure back in play. On the fundamentals, the specific datapoints that break the thesis at the ~2026-10-22 print: FY26 adjusted EPS guided back under $5.25, the consolidated MCR guide lifted above 92.6%, Medicaid MCR printing above the 92.9% FY guide, or Marketplace MCR guided above 90.0%. And there is a quieter failure mode: if the October print holds every number and the shares still cannot reclaim $213, the market is declining to underwrite the >$10 2027 framing, which is the only remaining reason to own the story.\n\n## Correlation Notes\n- Moves with CNC, ELV, UNH and CVS on shared cost-trend headlines; the mid-July Elevance Q2 produced a premarket decline of as much as 9% in MOH, larger than any major peer, reflecting the Medicaid concentration.\n- Policy beta is the dominant non-earnings driver: ACA subsidy legislation, CMS Medicare rate notices, and state Medicaid rate actions each move the name without a company event.\n- Index membership sits in the S&P MidCap 400 since 2026-07-16; flow arrives through mid-cap vehicles rather than large-cap ones, which thins the bid on sector-wide risk-off days.\n- Essentially no linkage to the AI/mega-cap complex driving broad index returns; the 17.5% distance from the 52-week high is sector-specific damage.",
  "first_seen": "2026-04-30",
  "last_analyzed": "2026-08-23T14:19:38+00:00",
  "last_synthesized": "2026-08-23",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}